- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
- Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
- Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
- New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
- Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
- Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
- Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
- Biogen to Realign Resources for Alzheimer's Disease Franchise
- Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
- CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
More ▼
Key statistics
On Monday, Biogen Inc (BIIB:NSQ) closed at 231.53, 22.22% above the 52 week low of 189.44 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 230.71 |
---|---|
High | 232.75 |
Low | 228.97 |
Bid | 231.44 |
Offer | 231.55 |
Previous close | 230.57 |
Average volume | 1.08m |
---|---|
Shares outstanding | 145.60m |
Free float | 145.37m |
P/E (TTM) | 28.16 |
Market cap | 32.81bn USD |
EPS (TTM) | 8.00 USD |
Data delayed at least 15 minutes, as of May 20 2024 20:53 BST.
More ▼